I agree. 5 million MC, if the P3 design is approved it’ll be very likely P3 will be succesfull. With potential annual revenues of upto $400m, market cap will explode.
Jackpot! ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug “we believe Gencaro could potentially provide a new standard of treatment for AF prevention for the estimated 2.5 million HFmrEF patients in the major markets in U.S., Europe and Japan” P was 0.017! And 58% better results than the actieve comparator In P2!”
Should go to $2-4/share now with only 14million shares outstanding